Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 17/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436197 | 0.87 | CYP1A2 (0.38) | AOC3CYP1A2CYP3A4GAACYP2C9 | |
| SCHEMBL3436175 | 0.82 | ALDH1A1 (0.38) | AOC3CYP1A2CYP3A4GAACYP2C9 | |
| SCHEMBL3436639 | 0.81 | CYP1A2 (0.37) | AOC3CYP1A2CYP3A4GAACYP2C9 | |
| SCHEMBL3436485 | 0.81 | CYP1A2 (0.42) | CYP1A2CYP3A4GAACYP2C9CYP2C19 | |
| SCHEMBL13999570 | 0.79 | ALDH1A1 (0.38) | AOC3CYP1A2CYP3A4GAACYP2C9 | |
| SCHEMBL3436581 | 0.76 | ALDH1A1 (0.38) | AOC3CYP1A2CYP3A4GAACYP2C9 | |
| SCHEMBL3556935 | 0.75 | CYP1A2 (0.38) | CYP1A2CYP3A4GAACYP2C9CYP2C19 | |
| SCHEMBL5228101 | 0.74 | MEN1 (0.55) | GAAALDH1A1MEN1KMT2A | |
| SCHEMBL3556537 | 0.74 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2A | |
| SCHEMBL3436297 | 0.74 | KMT2A (0.47) | CYP1A2CYP3A4GAACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | AOC3 2443/4885CYP1A2 1955/4885CYP3A4 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.